Business
UPDATE - Eco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman
UPDATE - Eco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman.
About this update from Enzolytics Inc.
[{"type":"text","content":"\n \n \n UPDATE - Eco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman\n \n \nUPDATE - Eco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman\n\nECPO Chairman and CEO Addresses Shareholders Informing Them of New Business Model\n\n \n MONROVIA, CA--(Marketwired - Jun 19, 2017) - Eco Petroleum Solutions, Inc. (OTC PINK: ECPO) published today the first letter to the shareholders from the newly appointed Chief Executive Officer and Chairman of ECPO, Harry Zhabilov. \n Dear Eco-Petroleum Shareholders,\n As the newly appointed CEO and Chairman of Eco-Petroleum Solutions, Inc. it is with great excitement that I address the shareholders of the Company and of Immunotech Laboratories, Inc. regarding our future potential as we transition ECPO into the Immunotherapy Medical Industry. \n IMMB is the exclusive license holder of an innovative US Patented treatment for HIV/AIDS and Hepatitis C which has successfully completed Phase III clinical testing at one of the leading Hospitals in Europe, the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases in Sofia, Bulgaria. A copy of the final report can be viewed at www.Immunotechlab.com and www.immunH.com. The participants in the Phase III testing were all salvage patients in various advanced stages of the HIV/AIDS virus. \n The final report issued by the Ministry of Health demonstrated improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK and of the index CD4/CD8. The patients demonstrated significant decreases in their viral loads. The treatment had a positive effect on opportunistic infections related to the progress of the HIV Virus and is compatible with other modern antiretroviral drugs currently in use. Patients had an exceptional tolerance to the treatment with a complete absence of any major side effects.\n In summary the report concluded that the test subjects, who were in the advanced stages of HIV/AIDS, experienced a virological effect with 80.5% achieving a drop in viral loads to below the threshold of detection and with 68% experiencing an increase in the strength of their immune system, as evidenced in the increase in CD4+T-lymphocytes. The treatment \"turns on\" the immune system to fight Autoimmune diseases which has not been ach...